Local Delivery Advantage ProteoThera’s MB platform enables converting systemic therapies into locally delivered proteins and small molecules, creating opportunities to partner with pharma companies seeking targeted PK improvements and safer profiles.

Gout Market Focus PRT-1000 targets acute gout pain, a growing market with large potential; position for licensing or co-development with companies aiming to expand their anti-inflammatory portfolios.

De-risked Partnerships Using already approved or validated therapies lowers regulatory and clinical risk, making ProteoThera an attractive partner for business development teams seeking faster time to value.

Academic Collaboration Platform origins at Brigham and Women’s Hospital and Harvard Medical School provide credibility and potential for academic partnerships or sponsored research/licensing deals.

Strategic Outsourcing With a small team and early-stage funding, ProteoThera can leverage CROs and strategic alliances to scale collaborations with larger pharma in autoimmune and tissue regeneration spaces.